BioAtla’s Executives Bet Big: CEO, CFO, and Chief Medical Officer Stack 1.1 Million Shares Amid Clinical‑Stage Volatility.
BioAtla insider buys reveal leadership confidence in its clinical‑stage pipeline, but investors must weigh the speculative risks and upcoming trial data for potential upside.
4 minutes to read